EWTX Stock Recent News

Does Edgewise Therapeutics, Inc. (EWTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 15, 2024, at 3:35 pm ET. The presentation will be webcast live; a link for the webcast can be found on the Edgewise events page and will be accessible for replay following the presentation. It is recommended that users connect to the webcast several.

The consensus price target hints at a 52.8% upside potential for Edgewise Therapeutics, Inc. (EWTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

The mean of analysts' price targets for Edgewise Therapeutics, Inc. (EWTX) points to a 33.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

The mean of analysts' price targets for Edgewise Therapeutics, Inc. (EWTX) points to a 70.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Edgewise (EWTX) will issue secondary shares to raise $240 million in gross proceeds. The capital will be used to fund key initiatives, including the potential commercial launch of lead pipeline drugs.

Edgewise Therapeutics, Inc. interim results from the phase 2 LYNX study, using EDG-5506 for the treatment of children ages 4 to 9 with DMD, are expected first half of 2024. Expansion opportunity exists to use EDG-5506 for the treatment of children and adolescent DMD patients ages 6 to 14 who have previously already been treated with gene therapy. It is expected that the global Duchenne Muscular Dystrophy treatment market size is expected to reach $3.89 billion by 2028.

Laura Chico, Wedbush Biotech Analyst, joins 'Closing Bell Overtime' to talk investing in biotech.

The average of price targets set by Wall Street analysts indicates a potential upside of 327.9% in Edgewise Therapeutics, Inc. (EWTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for the treatment of devastating muscle disorders, announced today that management will participate in fireside chats at two upcoming investor conferences: BofA Securities 2022 Healthcare Conference Presentation: Tuesday, May 9, 2023 at 8:55 am PDT (11:55 am ET) RBC Capital Markets Global Healthcare.